Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (1-10 of 466) with videos related to

Pageof 47
Sort By:
Haematologica|August 5, 2005
ZAP-70 methylation and expression status in chronic lymphocytic leukemiaStephan Stilgenbauer
Hematology. American Society of Hematology. Education Program|December 6, 2015
Prognostic markers and standard management of chronic lymphocytic leukemiaStephan Stilgenbauer
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Chemoimmunotherapy in chronic lymphocytic leukemiaStephan Stilgenbauer
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Advances in the use of alemtuzumab in CLLStephan Stilgenbauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group DefinitionStephan Stilgenbauer
Hematology. American Society of Hematology. Education Program|January 18, 2011
Understanding and managing ultra high-risk chronic lymphocytic leukemiaStephan Stilgenbauer, Thorsten Zenz
Hematology/Oncology Clinics of North America|August 25, 2004
Molecular genetics and its clinical relevanceStephan Stilgenbauer, Hartmut Döhner
The New England Journal of Medicine|August 9, 2002
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapyStephan Stilgenbauer, Hartmut Döhner
Leukemia & Lymphoma|August 25, 2009
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survivalThorsten Zenz, Stephan Stilgenbauer
Blood|October 1, 2011
Toward chemotherapy-free treatment of CLLStephan Stilgenbauer, Daniel Mertens
Pageof 47

Showing results (1-10 of 466) with videos related to

Sort By:
Pageof 47
Haematologica|August 5, 2005
ZAP-70 methylation and expression status in chronic lymphocytic leukemiaStephan Stilgenbauer
Hematology. American Society of Hematology. Education Program|December 6, 2015
Prognostic markers and standard management of chronic lymphocytic leukemiaStephan Stilgenbauer
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Chemoimmunotherapy in chronic lymphocytic leukemiaStephan Stilgenbauer
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Advances in the use of alemtuzumab in CLLStephan Stilgenbauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group DefinitionStephan Stilgenbauer
Hematology. American Society of Hematology. Education Program|January 18, 2011
Understanding and managing ultra high-risk chronic lymphocytic leukemiaStephan Stilgenbauer, Thorsten Zenz
Hematology/Oncology Clinics of North America|August 25, 2004
Molecular genetics and its clinical relevanceStephan Stilgenbauer, Hartmut Döhner
The New England Journal of Medicine|August 9, 2002
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapyStephan Stilgenbauer, Hartmut Döhner
Leukemia & Lymphoma|August 25, 2009
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survivalThorsten Zenz, Stephan Stilgenbauer
Blood|October 1, 2011
Toward chemotherapy-free treatment of CLLStephan Stilgenbauer, Daniel Mertens
Pageof 47